We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Influence of Transmission Season on Outcome of Treatment of Schistosoma Haematobium Infection in Mozambique

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00231322
Recruitment Status : Completed
First Posted : October 4, 2005
Last Update Posted : April 20, 2007
Durban University of Technology
Information provided by:
DBL -Institute for Health Research and Development

Brief Summary:
To assess the influence of seasonal variations in Schistosoma haematobium transmission on treatment outcome (morbidity and re-infection)

Condition or disease Intervention/treatment Phase
Hematuria Hydronephrosis Drug: praziquantel Not Applicable

Detailed Description:

General objective To provide knowledge about the influence of transmission season (high and low) on the outcome of treatment assessed by cure rate, re-infection rate, regression and reappearance of urinary tract morbidity rate after treatment in order to optimise praziquantel treatment strategies for morbidity control in urinary schistosomiasis.

Specific objectives To determine the prevalence and intensity of Schistosoma haematobium infection before chemotherapy and compare cure rates and levels of re-infection after chemotherapy administered during high and low transmission seasons.

To assess urinary tract morbidity due to Schistosoma haematobium by ultrasonography and compare the regression and reappearance of urinary tract pathology chemotherapy administered during high and low transmission seasons.

To correlate morbidity determined by ultrasound with infection and morbidity parameters such as intensity of infection, micro- and macrohematuria, circulating cathodic antigen (CCA) in urine, proteinuria and leucocyturia and determine sensitivity, specificity and positive predictive values in relation to urinary tract morbidity.

Study design The main research question concerning the influence of transmission season on treatment outcome will be addressed in a consecutive cohort study with two separate but comparable cohorts. The first cohort will be examined and treated with praziquantel during the season with high transmission, February/Mach (group A) and the second cohort will be examined and treated during the low transmission season, in July approximately 5 months later (group B). Each cohort will be examined before treatment and 2, 6 and 18 months after treatment.

The study will be carried out in 4 primary schools; two from Machava J area and two from Costa do Sol area. The schools will be selected based on the following criteria: similar prevalence (> 50%) and intensity of S. haematobium infection; absence or very low levels of S. mansoni infection; a minimum of 2 classes (>35 pupils per class) at each level (3rd and 4th level) and similar distribution of boys and girls.Examinations will include urine for parasitology and haematuria and ultrasonography of upper and lower urinary tract

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 520 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Influence of Transmission Season on Outcome of Schistosoma Haematobium Infection Treatment Among School Children in Urban and Peri-Urban Areas of Maputo and Matola, Mozambique
Study Start Date : March 2004
Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. cure rate
  2. egg reduction rate
  3. re-infection prevalence and intensity of infection *resolution of urinary tract pathology
  4. re-appearance of pathology after re-infection.

Secondary Outcome Measures :
  1. reduction in worm burden (CAA);

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • children aged 8-12 years

Exclusion Criteria:

  • All children presenting with macro-haematuria or severe pathology detected by ultrasonography (large masses, pseudo-polyps or hydronephrosis/hydroureter) at the 6 months follow-up examination will be treated with praziquantel and excluded in the data analysis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00231322

Layout table for location information
Maputo, Maputo Province, Mozambique
Sponsors and Collaborators
DBL -Institute for Health Research and Development
Durban University of Technology
Layout table for investigator information
Principal Investigator: Gerito Augusto, Msc Instituto Nacional de Saúde
Additional Information:
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00231322    
Other Study ID Numbers: 30/CNSB/03/624-03-0021
First Posted: October 4, 2005    Key Record Dates
Last Update Posted: April 20, 2007
Last Verified: April 2007
Keywords provided by DBL -Institute for Health Research and Development:
Schistosoma haematobium
Vesical polyps
Additional relevant MeSH terms:
Layout table for MeSH terms
Schistosomiasis haematobia
Urination Disorders
Urologic Diseases
Pathologic Processes
Kidney Diseases
Trematode Infections
Parasitic Diseases
Urinary Tract Infections
Vector Borne Diseases
Antiparasitic Agents
Anti-Infective Agents